Evidence map›Paper›PMID 35117905›Full record

ArticleTranslational cancer research2020

Incidence and prognostic factors of hepatoid adenocarcinoma: a population-based analysis.

Wenting Wang, Guang Li

Abstract read
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. A rare case of hepatoid adenocarcinoma of the lung.The clinical respiratory journal · 2023
    Article
  10. Article
  11. Article
  12. Hepatoid adenocarcinoma: A wolf in hepatocellular carcinoma's clothing.JGH open : an open access journal of gastroenterology and hepatology · 2022
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wenting WangDepartment of Radiation Oncology, The First Hospital of China Medical University, Shenyang, China.
Guang LiDepartment of Radiation Oncology, The First Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatoid adenocarcinoma (HAC) is a kind of rare extrahepatic adenocarcinoma with hepatocyte differentiation. At present, the incidence and prognostic factors of HAC remain poorly discussed.

methodsWe extracted two cohorts from Surveillance, Epidemiology, and End Results (SEER) database by restricting the histology to HAC. One cohort of 258 eligible patients was from SEER 21 Regs Limited-Field Research Data + Hurricane Katrina Impacted Louisiana Cases [2000-2016] to compute incidence, and the other cohort of 121 eligible patients was from SEER 18 Regs Custom Data (with additional treatment fields) [1975-2016] to estimate survival and risk factors. The incidence wad computed by the Joinpoint Regression Program (Version 4.7.0.0). The overall survival (OS) and prognostic factors were analyzed by univariate and multivariate analyses in SPSS 24.0.

resultsThe overall incidence of HAC between 2000 and 2016 was 0.014 per 100,000 people (95% CI: 0.012 to 0.015). The most common primary site was the lung, followed by the digestive, urinary and reproductive organs, but in the previously published case reports, the stomach was the most common site. The median age at diagnosis was 66 (range, 31-85) years. A total of 28.1% of patients underwent surgery, while 71.9% underwent radiotherapy or/and chemotherapy. The 1-year survival rate of these patients was 35.0%, and the 3-year survival rate was only 16.9%. The median survival time was 5 months (95% CI: 2.97 to 7.03 months). Multivariate analysis showed that age less than 60 years, no distant metastasis, surgery and chemotherapy were independent prognostic factors related to a better outcome.

conclusionsThis study suggests that HAC is a rare malignant tumor with poor prognosis, and its most common site is lung. Its incidence is increasing year by year. Age at diagnosis, distant metastases, surgery, and chemotherapy were independent prognostic factors.

Indexed as

clinical characteristicsHepatoid adenocarcinomaincidenceprognosisSEER

Identifiers

PMID35117905
PMCPMC8798184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.